alovudine has been researched along with mln 8237 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolen, JB; Chakravarty, A; Chen, W; Claiborne, CF; Ecsedy, JA; Germanos, MS; Gershman, RE; Hoar, KM; Huck, JJ; Hyer, ML; Janowick, DA; Leroy, PJ; Manfredi, MG; Sells, TB; Shinde, V; Silva, MD; Silverman, L; Stroud, SG; Wysong, DR; Zhang, M | 1 |
1 other study(ies) available for alovudine and mln 8237
| Article | Year |
|---|---|
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Topics: Animals; Aurora Kinase A; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Female; Fluorine Radioisotopes; HCT116 Cells; HeLa Cells; Humans; Lymphoma; Mice; Mice, Nude; Mice, SCID; Mitotic Index; Molecular Structure; Neoplasms; Phosphorylation; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Pyrimidines; Spindle Apparatus; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |